Discovery of Jatrophane Diterpenoids as JAG1-Notch Signaling Inhibitors for the Treatment of Liver Fibrosis

View at publisher
Authors: Xinying Zhu, Shu-Qi Wu, Lu Gan, Xianyuan Yang, Yi-Ling Liao, Nan An, Run‐Zhu Fan, Jia-Luo Huang, Gui‐Hua Tang, Chuan‐Rui Zhang, Sheng Yin
Cited by: 1
References: 44

Abstract

Liver fibrosis is an urgent clinical condition that lacks effective therapies. In this study, molecular networking-guided fractionation of the medicinal plant Euphorbia hylonoma yielded a focused jatrophane diterpenoid library ( 1 – 32 ), featuring 26 previously undescribed structures. Subsequent antifibrotic screening of this library in TGF-β1-stimulated hepatic stellate cells (HSCs) identified euphylonoid D ( 1 ) as a novel hit, enabling a preliminary structure–activity relationship (SAR) analysis of this class. In a CCl 4 -induced mouse model, 1 significantly alleviated liver fibrosis while exhibiting a favorable safety profile. Mechanistic studies revealed that 1 acts as the first small-molecule inhibitor of Jagged-1 (JAG1), a classic Notch ligand, thereby suppressing Notch signaling, leading to the attenuation of liver fibrosis. These findings not only validate JAG1 as a therapeutic target for liver fibrosis but also highlight 1 as a promising lead for developing novel antifibrotic agents.

Fields of Study & Subjects

Bioactive Natural Diterpenoids Research Cell death mechanisms and regulation Drug-Induced Hepatotoxicity and Protection

Publication details

Journal / source
Journal of Medicinal Chemistry
Publisher
American Chemical Society (ACS)
Volume
69
Issue
13
Pages
15825–15839
Publication date
18 June 2026
Language
EN